



## SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition

DUBLIN, Calif., Dec. 2 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present three posters at the 50th American Society of Hematology (ASH) Annual Meeting & Exposition on December 7 and 8, 2008.

SuperGen's presentations will review clinical and non-clinical advances in the following compounds: SGI-1776, SGI-1252, and SGI-110. All presentations will occur as poster presentations.

Abstract Number/Title	Date
Abstract 1922: Inhibiting PIM-1 is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target	Dec 7
Abstract 2629: Preclinical Characterization of the JAK-2 Inhibitor, SGI-1252	Dec 7
Abstract 3355: Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat	Dec 8

### About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit <http://www.supergen.com>.

### Contacts:

SuperGen, Inc.  
Timothy L. Enns  
SVP, Corporate Communications  
& Business Development  
Tel: (925) 560-2810  
Email: [tenns@supergen.com](mailto:tenns@supergen.com)

Dorland Global Public Relations  
Michael Beckerich (Media)  
Tel: (212) 677-7632  
[mbeckerich@dorland.com](mailto:mbeckerich@dorland.com)

SOURCE SuperGen, Inc.

Web site: <http://www.supergen.com>  
<http://www.prnewswire.com>